Literature DB >> 16699725

The -822G/A polymorphism in the promoter region of the MAP4K5 gene is associated with reduced risk of type 2 diabetes in Chinese Hans from Shanghai.

Yanyun Gu1, Tianhong Luo, Jian Yang, Di Zhang, Meng Dai, Weixia Jian, Sheng Zheng, Wenzhong Zhou, Weibin Zhou, Yixing Wu, Yun Liu, Youping Liu, Jiping Li, Xiaoyan Xie, Guo Li, Min Luo.   

Abstract

MAP4K5 (mitogen-activated protein kinase kinase kinase kinase 5), an early component of MAP kinase signal cascades was shown to activate Jun kinase in mammalian cells. The association between SNPs of MAP4K5 and type 2 diabetes (T2DM) was investigated due to the known relationship of the JNK pathway with T2DM. A total of 1,399 cases were included in the study. Oral glucose tolerance test (OGTT) and insulin release test (IRT) were performed, and blood DNA samples were extracted and genotyped on the MAP4K5 -822G/A site. These cases were subdivided into central-obesity and nonobesity groups, based upon their individual waist circumference. Allele-specific real-time PCR was employed for genotyping. No difference was found between the two groups in the distribution of three genotypes on MAP4K5 -822G/A. In the central-obesity group, fewer diabetic patients (38.9%) were present in the AA genotype group than the GG/GA group (58.5%, P=0.024). Glucose levels after 30 and 60 min of 75 g glucose tolerance, area under the curve for glucose, and insulin secretion indexes were lower (P<0.05) in AA than those in GG/GA genotype group in the central-obesity cases. Other variables did not show significant differences between the two groups. In the Han population from Shanghai, the AA genotype of MAP4K5 -822G/A in central-obesity cases appears less likely to develop diabetes compared with the other genotypes. Therefore, the G allele may be a factor that does not protect central-obesity cases from developing into diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699725     DOI: 10.1007/s10038-006-0402-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  28 in total

1.  Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.

Authors:  M Stumvoll; A Mitrakou; W Pimenta; T Jenssen; H Yki-Järvinen; T Van Haeften; W Renn; J Gerich
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

2.  A dual role for TNF-alpha in type 1 diabetes: islet-specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis.

Authors:  U Christen; T Wolfe; U Möhrle; A C Hughes; E Rodrigo; E A Green; R A Flavell; M G von Herrath
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

3.  Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function.

Authors:  Hirofumi Noguchi; Yusuke Nakai; Shinichi Matsumoto; Miho Kawaguchi; Michiko Ueda; Teru Okitsu; Yasuhiro Iwanaga; Yukihide Yonekawa; Hideo Nagata; Kohtaro Minami; Yumi Masui; Shiroh Futaki; Koichi Tanaka
Journal:  Am J Transplant       Date:  2005-08       Impact factor: 8.086

4.  Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity.

Authors:  Bronwen Dalziel; Alison K Gosby; Rosemary M Richman; Janet M Bryson; Ian D Caterson
Journal:  Obes Res       Date:  2002-05

5.  Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes.

Authors:  Anja Jaeschke; Mercedes Rincón; Beth Doran; Judith Reilly; Donna Neuberg; Dale L Greiner; Leonard D Shultz; Aldo A Rossini; Richard A Flavell; Roger J Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-02       Impact factor: 11.205

6.  IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death.

Authors:  K Suk; S Kim; Y H Kim; K A Kim; I Chang; H Yagita; M Shong; M S Lee
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

7.  The tumour necrosis factor alpha -238 G --> A and -308 G --> A promoter polymorphisms are not associated with insulin sensitivity and insulin secretion in young healthy relatives of Type II diabetic patients.

Authors:  M Koch; K Rett; A Volk; E Maerker; K Haist; M Weisser; A Rettig; W Renn; H U Häring
Journal:  Diabetologia       Date:  2000-02       Impact factor: 10.122

8.  Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2).

Authors:  Chong-Shan Shi; John H Kehrl
Journal:  J Biol Chem       Date:  2003-02-18       Impact factor: 5.157

9.  A central role for JNK in obesity and insulin resistance.

Authors:  Jiro Hirosumi; Gürol Tuncman; Lufen Chang; Cem Z Görgün; K Teoman Uysal; Kazuhisa Maeda; Michael Karin; Gökhan S Hotamisligil
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

Review 10.  Targeting JNK for therapeutic benefit: from junk to gold?

Authors:  Anthony M Manning; Roger J Davis
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

View more
  3 in total

Review 1.  The mammalian family of sterile 20p-like protein kinases.

Authors:  Eric Delpire
Journal:  Pflugers Arch       Date:  2009-04-28       Impact factor: 3.657

2.  TS: a powerful truncated test to detect novel disease associated genes using publicly available gWAS summary data.

Authors:  Jianjun Zhang; Xuan Guo; Samantha Gonzales; Jingjing Yang; Xuexia Wang
Journal:  BMC Bioinformatics       Date:  2020-05-04       Impact factor: 3.169

3.  Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia.

Authors:  Zhenjie Bai; Qingmei Yao; Zhongyi Sun; Fang Xu; Jicheng Zhou
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.